Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor

Imatinib resistance due to a novel tri-nucleotide insertion in the SH2/C lobe interface of BCR/ABL kinase domain between position K357 and N358

(2012) Shantashri Vaidya et al.   LEUKEMIA RESEARCH

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

(2012) Filip Razga et al.   Molecular Diagnosis & Therapy

Characteristics of BCR–ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients

(2010) YaZhen Qin et al.   ANNALS OF HEMATOLOGY

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

(2010) D. W. Sherbenou et al.   BLOOD

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

(2009) Alfonso Quintás-Cardama et al.   CANCER

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent

(2009) Soo-Hyun Kim et al.   HEMATOLOGICAL ONCOLOGY

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

(2008) E. Jabbour et al.   BLOOD

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

(2008) D W Sherbenou et al.   LEUKEMIA